KRS 311.774: Report on prescriptions for abortion-inducing drugs -- Information on

potential reversal of effect of drugs to be included with prescription --

Complications and adverse events to be reported to Vital Statistics

Branch.

(1) Each prescription issued for an abortion-inducing drug as defined in KRS

311.7731 for which the primary indication is the induction of abortion as defined

in KRS 311.720 shall be reported on a report form provided by the cabinet

within three (3) days after the prescription was issued. The report form shall be

signed by the qualified physician who provided the abortion-inducing drug and

transmitted to the cabinet within three (3) days after the drug was provided.

Each report shall include at minimum the information required by KRS 213.101.

(2) Information on the potential ability of a physician to reverse the effects of

abortion-inducing drugs as defined in KRS 311.7731 for which the primary

indication is the induction of abortion, including where additional information

about this possibility may be obtained and contact information for assistance in

locating a physician who may aid in the reversal, shall be provided with each

prescription issued for an abortion-inducing drug for which the primary

indication is the induction of abortion as defined in KRS 311.720.

(3) For each abortion reported to the Vital Statistics Branch as required by KRS

213.101, the report shall also state whether any abortion complication or

adverse event as defined in KRS 311.7731 or medical treatment was known to

the provider as a result of the abortion. The report shall be completed and

signed by the physician, qualified physician, or other healthcare provider who

diagnosed or treated the complication or adverse event.

(4) The report shall include at a minimum the information required by KRS

213.101 and:

(a) Whether a complication or adverse event as defined in KRS 311.7731

occurred during the abortion procedure or while the pregnant patient was

still at the facility where the abortion was performed and the level of

intervention required to attend to the complication or adverse event:

1. Emergency medical services;

2. Stabilization on site;

3. Transport to another medical facility;

4. Urgent care follow-up; and

5. Primary care provider;

(b) The date the pregnant patient presented for diagnosis or treatment for the

complication or adverse event;

(c) Whether the complication or adverse event was previously managed by

the qualified physician who provided the abortion-inducing drug as

defined in KRS 311.7731 or a backup qualified physician;

(d) The amount billed to cover the treatment for specific complications,

including whether the treatment was billed to Medicaid, private insurance,

private pay, or other method. This should include the ICD-10 codes

reported and charges for any physician, hospital, emergency room,

prescription or other drugs, laboratory tests, and any other costs for

treatment rendered; and

(e) A list of complications, adverse events, or treatments that occurred, a list

of any emergency transfers, and any follow-up treatment provided

including whether any additional drugs were provided in order to complete

the drug-induced abortion.